Press Releases BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Market Closed - Toronto S.E. Other stock markets 01:29:59 16/05/2024 am IST			5-day change	1st Jan Change
2.3 ^CAD	-19.58%		-25.32%	-70.51%

15/05	BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	MT
24/04	BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	15/05	AQ
BriaCell Announces Oral and Poster Presentations at ASCO 2024	24/04	AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	10/04	AQ
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR	09/04	AQ
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	03/04	PU
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies	07/03	AQ
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference	06/03	AQ
BriaCell Provides Update on Alleged Illegal Trading of Public Securities	27/02	AQ
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07/02	AQ
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing	06/02	AQ
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting	31/01	AQ
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer	04/01	AQ
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12	AQ
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset	20/12	AQ
BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 - Form 8-K	15/12	PU
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	06/12	AQ
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit	06/12	AQ
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor	30/11	AQ
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND	03/11	AQ
BriaCell Therapeutics : BRIAPRO THERAPEUTIC CORP. FINANCIAL STATEMENTS FOR THE PERIOD ENDED JULY 31, 2023 - Form 8-K	26/23/26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Press Releases

Filters